ProfileGDS5678 / 1436682_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 72% 73% 71% 72% 78% 74% 73% 74% 72% 73% 72% 74% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8043274
GSM967853U87-EV human glioblastoma xenograft - Control 24.5834172
GSM967854U87-EV human glioblastoma xenograft - Control 34.6513173
GSM967855U87-EV human glioblastoma xenograft - Control 44.5083371
GSM967856U87-EV human glioblastoma xenograft - Control 54.5646372
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1974978
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7238774
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6616173
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7982674
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.5531272
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.640673
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.6574572
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.856574
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6729473